Seqirus To Invest $140 Million to Expand Flu Vaccine Manufacturing
Seqirus, a subsidiary of CSL Limited and developer and manufacturer of influenza vaccines, is planning a $140-million expansion of its manufacturing facility in Holly Springs, North Carolina, as part of a plan to meet demand for Seqirus’ cell-based quadrivalent influenza vaccine (QIVc). CSL acquired the Holly Springs facility from Novartis in 2015.
Seqirus was formed in 2015 following CSL’s $275-million acquisition of the Novartis’ influenza vaccines business and its subsequent integration with bioCSL, a CSL subsidiary. The acquisition included Novartis’ influenza vaccine-manufacturing facility in Holly Springs.
The $140-million expansion will allow Seqirus to increase capacity for formulation and fill/finish manufacturing of cell-based and adjuvanted influenza vaccines for global markets. Seqirus says the development will create 120 permanent skilled jobs, adding to the current workforce at the site of more than 600 employees. Construction of the new facility is expected to be completed by 2020 to support increased fill/finish of influenza vaccine doses as well as production of pandemic influenza vaccines.
The Holly Springs manufacturing facility was purpose-built in partnership with the Biomedical Advanced Research and Development Authority (BARDA) to combat pandemic influenza threats. BARDA is part of the Office of the Assistant Secretary for Preparedness and Response within the US Department of Health and Human Services.